Assessment of changes in quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis. by Vigil, Erin M. et al.
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Journal Articles: Ophthalmology Ophthalmology 
3-18-2015 
Assessment of changes in quality of life among patients in the 
SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a 
randomized study to assess the safety and bioactivity of 
intravitreal and subconjunctival injections of sirolimus in patients 
with non-infectious uveitis. 
Erin M. Vigil 
Johns Hopkins University 
Yasir J. Sepah 
University of Nebraska Medical Center, yasir.sepah@unmc.edu 
Anthony L. Watters 
Johns Hopkins University 
Mohammad A. Sadiq 
University of Nebraska Medical Center, ali.sadiq@unmc.edu 
Mehreen Ansari 
Johns Hopkins University 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.unmc.edu/com_eye_articles 
 Part of the Ophthalmology Commons 
Recommended Citation 
Vigil, Erin M.; Sepah, Yasir J.; Watters, Anthony L.; Sadiq, Mohammad A.; Ansari, Mehreen; Bittencourt, 
Millena G.; Ibrahim, Mohamed A.; Do, Diana V.; and Dong Nguyen, Quan, "Assessment of changes in 
quality of life among patients in the SAVE Study - Sirolimus as therapeutic Approach to uVEitis: a 
randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of 
sirolimus in patients with non-infectious uveitis." (2015). Journal Articles: Ophthalmology. 26. 
https://digitalcommons.unmc.edu/com_eye_articles/26 
This Article is brought to you for free and open access by the Ophthalmology at DigitalCommons@UNMC. It has 
been accepted for inclusion in Journal Articles: Ophthalmology by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
Authors 
Erin M. Vigil, Yasir J. Sepah, Anthony L. Watters, Mohammad A. Sadiq, Mehreen Ansari, Millena G. 
Bittencourt, Mohamed A. Ibrahim, Diana V. Do, and Quan Dong Nguyen 
This article is available at DigitalCommons@UNMC: https://digitalcommons.unmc.edu/com_eye_articles/26 
ORIGINAL RESEARCH Open Access
Assessment of changes in quality of life among
patients in the SAVE Study - Sirolimus as
therapeutic Approach to uVEitis: a randomized
study to assess the safety and bioactivity of
intravitreal and subconjunctival injections of
sirolimus in patients with non-infectious uveitis
Erin M Vigil1,2, Yasir Jamal Sepah3, Anthony L Watters2,4, Mohammad A Sadiq3, Mehreen Ansari2,
Millena G Bittencourt2, Mohamed A Ibrahim3, Diana V Do3 and Quan Dong Nguyen3*
Abstract
Background: The National Eye Institute 39-Question Visual Function Questionnaire (NEI VFQ-39) is an indicator of
vision-related quality of life (QoL). The NEI VFQ-39 is used to assess the QoL in patients with non-infectious posterior uveitis,
intermediate uveitis, or panuveitis, treated with subconjunctival (SCJ) or intravitreal (IVT) sirolimus as an immunomodulatory
therapeutic (IMT) agent, delivered subconjunctivally (SCJ) or intravitreally (IVT) (the SAVE Study). Thirty subjects with
non-infectious uveitis were randomized (SCJ:IVT, 1:1) for a prospective clinical trial. The 39-Question Visual Function
Questionnaire (VFQ-39) was administered at baseline (BL), month 6 (M6), and month 12 (M12) visits. The survey measures
self-reported vision health status for patients with chronic eye disease and assesses the effects of visual impairment on
both task-oriented visual function and general health domains. In accordance to the NEI-VFQ Manual, each patient’s
questionnaire was converted to a scaled score between 0 (worst) and 100 (best), and median scores were calculated for
each of the subcategories and overall composite score at BL, M6, and M12. Wilcoxon signed-rank test was performed.
Results: Twenty-six patients completed the VFQ-39 at BL and M6, whereas 23 patients completed it at M12. Patients
showed a significant improvement in pooled composite scores from BL to M6 and BL to M12. Analysis by treatment groups
showed that intravitreal injection of sirolimus is better tolerated.
Conclusions: Sirolimus has demonstrated bioactivity as an IMT and corticosteroid-sparing agent to treat non-infectious
uveitis. Patients receiving intravitreal injection of sirolimus showed overall improvement of vision-related health while
those receiving subconjunctival injections did not. Larger randomized control trials with sirolimus are indicated to validate
these results.
Trial registration: ClinicalTrials.gov: NCT00908466
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Background
Uveitis is an ocular disease that results from inflammation
and tissue damage, which compromises the uvea of the eye
[1]. Uveitis is the fourth most common cause of blindness
among the working-age population in the developed world
[2]. It is responsible for approximately 10% of the cases of
blindness in USA [2]. Non-infectious uveitis may be an
ocular manifestation of one of various autoimmune dis-
eases, such as reactive arthritis, ankylosing spondylitis, Beh-
çets syndrome, and inflammatory bowel disease, or it can
limit exclusively to the ocular structures.
Topical, periocular, intraocular, and systemic corticoste-
roids are the mainstay of primary immunosuppressive
therapy as well as the only United States Federal Drug
Agency (US-FDA)-approved drug class in the United
States for treatment of non-infectious uveitis [3]. However,
corticosteroid treatment induces a high rate of adverse
effects such as increased intraocular pressure, cataracts,
Cushingoid syndrome, diabetes, osteoporotic bones, con-
gestive heart failure, and metabolic disturbances [2,4].
Consequently, newer steroid-sparing agents (such as siro-
limus, adalimumab, and gevokizumab) are being devel-
oped and evaluated for the treatment of non-infectious
uveitis.
Sirolimus is an immunosuppressant that works through
its inhibition of the mammalian target of rapamycin
(mTOR) and subsequent inhibition of inflammatory cyto-
kine production [5]. Sirolimus inhibits the inflammatory
process and can be delivered both intravitreally and sub-
conjunctivally. Subconjunctival and intravitreal sirolimus
have demonstrated evidences of safety and efficacy in pa-
tients with non-infectious uveitis [6].
The National Eye Institute Visual Function Question-
naire 39-Item (NEI VFQ-39 or NEI VFQ-25 + additional
items) is a self-administered survey that has been widely
used to assess patient vision-related functioning. The NEI
VFQ-39 survey contains 39 questions that evaluate 12
subscales of quality of life (QoL) including general health,
general vision, ocular pain, near vision, distance vision, so-
cial function, mental health, role difficulty, dependency,
driving, color vision, and peripheral vision. Each question
has multiple choices that are scored on a five-, six-, or
ten-point scale.
The NEI-VFQ has been used previously in several stud-
ies to assess the impact of ocular disorders and their treat-
ments on visual function. These studies indicate that the
questionnaire is a reliable and valid indicator of vision-
related quality of life in patients with non-infectious uve-
itis and other ocular diseases [7-9].
The index analysis was performed to assess changes in
QoL of patients receiving sirolimus as a therapy for non-
infectious uveitis in the SAVE (Sirolimus as therapeutic Ap-
proach to uVEitis) study using patient-reported changes in
QoL as an indicator.
Methods
A randomized, open-label safety, and bioactivity clinical
study was conducted at the Wilmer Eye Institute on 30
patients with non-infectious intermediate uveitis, poster-
ior uveitis, and panuveitis in accordance with the SAVE
Study protocol [10]. These patients were stratified at
baseline on disease activity and the use of prednisone
and/or other IMT agents into three categories: category
1: active uveitis and receiving no treatment; category 2:
active uveitis and receiving ≥10 mg/day of prednisone
and/or at least one other systemic immunosuppressant;
or category 3: inactive uveitis and receiving <10 mg/day
of prednisone and/or at least one other systemic im-
munosuppressant. Patients were required to discontinue
all systemic immunosuppressants other than corticoste-
roids 30 days prior to the first study drug administration
at baseline.
Active disease was defined as having at least 1+ vitreous
haze using the Standardized Uveitis Nomenclature (SUN)
Working Group scale and/or at least 1+ vitreous cell
count using the Foster and Vitale scale. Inactive disease
was defined as having vitreous haze of 0.5+ or less and vit-
reous cell count of 0.5+ or less, using the SUN Working
Group and Foster and Vitale scales.
Patients were randomized and divided into two treatment
groups. Group 1 received intravitreal (IVT) injections of
352 μg of sirolimus in the study eye on days 0, 60, and 120.
Group 2 received subconjunctival (SCJ) injections of 1,320
μg of sirolimus in the study eye on days 0, 60, and 120.
Starting at day 180, study subjects were eligible to receive
additional subconjunctival or intravitreal sirolimus, based
on their initial group randomization, every 2 months if they
were found to have active disease as defined above. The
end-of-study visit was at month 12.
The NEI VFQ 39 was self-administered at baseline (BL),
month 6 (M6), and month 12 (M12) of the study. Patient
composite and subscale scores were calculated according
to the protocol in the NEI VFQ Manual [11]. The mean
scores of all subscales were calculated for each category.
All items are scored so that a high score represents better
functioning, for example, a high ocular pain score would
indicate minimal pain experienced by the patient. Each
item is then converted to a 0 to 100 scale so that the low-
est and highest possible scores are set at 0 and 100 points,
respectively. The composite score was calculated by aver-
aging the scores of the 12 subscales.
Pooled patient data was analyzed to assess response to
study treatment regardless of study group or category.
Subsequently, patient data was divided into treatment
groups (SCJ vs IVT) and treatment categories and then
analyzed for differences in subscale and composite scores.
The Wilcoxon signed-rank test was used to determine
significance of changes between baseline, month 6, and
month 12 for all groups. A 95% confidence interval with
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a 5% level of significance was used, therefore, a P value
of <0.05 was considered significant.
Results
The VFQ-39 was filled by 26 patients at BL and M6 and
by 23 patients at M12. A total of six patients had exited
the study before the M12 endpoint and one patient did
not fill out the M12 questionnaire.
Pooled data
Median subscale and composite scores for the pooled data
are shown in Table 1. Significant improvements in scores
were seen in the following subscales at both M6 and M12:
ocular pain, distance activities, and vision-specific mental
health. The pooled composite scores also showed signifi-
cant improvements at both M6 and M12 (P < 0.001).
Treatment groups
From BL to M12, patients in both groups reported a signifi-
cant increase (improvement) in the ocular pain scores. How-
ever, group 1 also reported significant improvements in the
areas of general vision, near activities, distance activities,
vision-specific social functioning, and vision-specific mental
health. Only group 1 displayed significant improvement in
composite score from BL to M12 (P= 0.01) (Table 2).
Disease category
From BL to M12, patients in category 1 and 2 showed a sig-
nificant increase (improvement) in ocular pain scores and
vision-specific mental health scores. However, only patients
in category 1 showed a significant increase in the NEI
VFQ-39 composite scores at month 12 (P = 0.03) (Table 3).
Discussion
In this QoL analysis of study subjects in the SAVE
Study, NEI VFQ-39 scores have demonstrated that both
intravitreal and subconjunctival injections of sirolimus
were well tolerated. After 12 months, pooled data from
patients treated with sirolimus (regardless of the mode
of injection) showed a statistically significant improve-
ment in composite scores for NEI VFQ-39 (P < 0.001).
Specifically, patients showed greatest score improve-
ments in the subscales of ocular pain and vision-specific
mental health (P < 0.001). Patients in group 2 showed a
greater increase in ocular pain scores from BL to month
6; however, the effect seemed to have plateaued off and
no significant improvement was observed in this group
beyond month 6. Group 1 continued to show improve-
ment until month 12. Improvements were also reported
in vision-specific social functioning, vision-specific role
difficulties, and vision-specific dependency.
When divided into treatment groups, it is apparent that
IVT injection of sirolimus showed a significant improve-
ment in a higher number of subscales at M12 compared to
SCJ administration. Patients receiving sirolimus injections in
both the groups showed a significant improvement in ocular
pain after 12 months (P < 0.01). In addition, patients receiv-
ing IVT injections (Group 1) show significant improvements
in overall vision-related functioning after 12 months com-
pared to baseline. Results indicate that sirolimus treatment
provides a significant decrease in ocular pain regardless of
route of administration. However, IVT injection results in
improvement in the additional areas of general vision, near
activities, distance activities, vision-specific social function-
ing, and vision-specific role difficulties.
Table 1 Pooled National Eye Institute 39-Question Visual Function Questionnaire composite and subscale scores
Median P value
VFQ-25 subscales BL (n = 26) M6 (n = 26) M12 (n = 23) BL-M6 BL-M12
General health 69.6 71.7 71.6 0.51 0.28
General vision 62.3 70.4 71.7 0.01 0.07
Ocular pain 73.1 82.2 86.4 0.03 <0.001
Near activities 70.0 71.2 75.0 0.65 0.12
Distance activities 73.8 79.7 81.3 0.03 0.02
Vision-specific social functioning 87.5 91.3 94.0 0.21 0.02
Vision-specific mental health 59.5 69.4 76.3 <0.001 <0.001
Vision-specific role difficulties 70.7 76.2 82.9 0.07 0.02
Vision-specific dependency 82.9 88.0 92.7 0.09 0.03
Drivinga 69.0 72.1 75.0 0.31 0.10
Color vision 90.4 95.2 94.6 0.23 0.16
Peripheral vision 78.8 82.7 79.3 0.39 0.75
Composite score for VFQ-39(VFQ-25 + additional items) 74.3 79.9 82.8 <0.001 <0.001
Italicized values indicate statistical significance.
aDriving: n = 21 for BL and M6, n = 18 for M12.
BL, baseline; M6, month 6; M12, month 12, VFQ, Visual Function Questionnaire.
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Table 2 The National Eye Institute 39-Question Visual Function Questionnaire composite and subscale scores divided
by treatment group
Group 1 Group 2





















General health 73.08 73.08 71.43 1.00 0.80 66.21 70.33 71.75 0.47 0.30
General vision 59.49 70.77 72.78 0.03 0.04 65.13 70.00 70.61 0.18 0.70
Ocular pain 78.85 79.81 88.54 0.79 0.01 67.31 84.62 84.09 0.01 0.01
Near activities 66.35 67.69 76.18 0.73 0.03 73.59 74.74 73.64 0.78 0.56
Distance activities 73.33 79.17 83.96 0.15 0.04 74.36 80.29 78.41 0.12 0.23
Vision-specific social functioning 85.26 89.10 95.49 0.44 0.03 89.74 93.59 92.42 0.31 0.28
Vision-specific mental health 59.68 68.08 78.33 0.07 0.01 59.23 70.77 74.09 0.02 0.06
Vision-specific role difficulties 71.63 75.48 85.42 0.42 0.04 69.71 76.92 80.11 0.07 0.22
Vision-specific dependency 80.29 87.02 92.71 0.16 0.07 85.58 88.94 92.61 0.38 0.26
Drivinga 79.63 81.48 80.21 0.56 0.52 64.58 72.22 70.00 0.08 0.54
Color vision 88.46 94.23 95.83 0.39 0.10 92.31 96.15 93.18 0.44 1.00
Peripheral vision 78.85 81.73 83.33 0.69 0.19 78.85 83.65 75.00 0.41 0.34
Composite score for VFQ-39 (VFQ-25 + additional items) 73.87 78.64 84.87 0.06 0.01 74.67 81.17 80.49 0.03 0.10
Italicized values indicate statistical significance.
aDriving (group 1): n = 9 for BL-M6 and n = 8 for BL-M12 comparison. Driving (group 2): n = 12 for BL-M6 and n = 10 for BL-M12 comparison.
BL, baseline; M6, month 6; M12, month 12, VFQ, Visual Function Questionnaire.
Table 3 The National eye institute 39-question visual function questionnaire scores analyzed by disease category
Category 1 Category 2 Category 3































General health 73.98 73.47 73.21 0.93 0.39 76.62 75.32 74.03 0.73 0.44 56.25 65.18 67.41 0.26 0.11
General vision 50.48 58.57 70.00 0.38 0.08 66.06 76.36 73.33 0.03 0.27 67.50 72.50 70.42 0.14 0.65
Ocular pain 64.29 78.57 78.13 0.10 0.04 80.68 87.50 94.32 0.14 0.001 70.31 78.13 79.69 0.43 0.27
Near activities 54.52 57.98 63.33 0.66 0.12 73.48 76.89 79.17 0.23 0.16 78.65 75.00 75.00 0.49 0.30
Distance activities 64.76 69.35 71.88 0.52 0.06 77.27 84.09 82.58 0.01 0.29 77.08 82.81 84.27 0.36 0.18
Vision-specific social functioning 79.76 84.52 83.33 0.52 0.10 87.12 94.70 96.21 0.10 0.07 94.79 92.71 96.35 0.68 0.55
Vision-specific mental health 34.76 47.14 51.25 0.16 0.05 64.09 73.18 81.36 0.07 0.02 74.69 83.75 81.88 0.02 0.30
Vision-specific role difficulties 47.32 52.68 64.06 0.36 0.11 80.11 85.80 89.20 0.22 0.19 78.13 83.59 83.59 0.41 0.33
Vision-specific dependency 66.96 74.11 75.00 0.31 0.10 82.39 88.64 94.89 0.27 0.13 97.66 99.22 98.44 0.45 0.60
Driving 56.55 55.56 47.22 1.00 0.42 81.48 74.24 78.03 0.36 0.49 65.48 84.72 83.33 0.03 0.08
Color vision 85.71 92.86 93.75 0.46 0.18 88.64 95.45 93.18 0.39 0.44 96.88 96.88 96.88 NS NS
Peripheral vision 75.00 82.14 75.00 0.57 0.64 84.09 87.50 84.09 0.57 1.00 75.00 76.56 75.00 0.83 1.00
Composite score for VFQ-39
(VFQ-25 + additional items)
61.83 68.70 71.09 0.21 0.03 78.18 84.03 86.03 0.03 0.08 79.78 84.04 84.13 0.15 0.09
Italicized values indicate statistical significance.
BL, baseline; M6, month 6; M12, month 12, VFQ, Visual Function Questionnaire, Category 1, active uveitis and receiving no treatment; Category 2, active uveitis
and receiving ≥10 mg/day of prednisone and/or at least one other systemic immunosuppressant; Category 3, inactive uveitis and receiving <10 mg/day of
prednisone and/or at least one other systemic immunosuppressant.
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In patients that received sirolimus subconjunctivally, the
most frequently reported adverse event was inflammation
at the injection site, manifesting as ocular discomfort; con-
junctival hyperemia and chemosis [6]. Such adverse events
are possible factors as to why patient-reported QoL scores
from patients receiving subconjunctival injections would
be lower than those receiving intravitreal injections.
Analyzing results by disease category showed that patients
in Category 1 exhibited the greatest increase in Qol scores
after treatment with sirolimus. Patients in this category had
active uveitis and were not receiving any treatment. It is pos-
sible that the absence of treatment in these patients may
have caused the substantially lower VFQ scores at BL and
therefore possibly providing more room for improvement
with sirolimus treatment. Conversely, improvements in QoL
scores may have been masked in patients that were using
corticosteroids (categories 2 and 3) due to steroid-related
adverse events over the course of the study.
While sirolimus has demonstrated bioactivity as an IMT
and corticosteroid-sparing agent to treat non-infectious
uveitis, the analyses from our NEI VFQ-39 assessments
have indicated that patients receiving sirolimus also show
an overall improvement of vision-related health.
Our study is among the very first being reported in the
literature on the assessment of QoL in patients with uve-
itis undergoing therapy with local administration of an
IMT. An important limitation of our study is the small
sample size. Due to the small sample size (n = 26), it is not
certain that these results are applicable to the larger popu-
lation of patients with non-infectious uveitis. Currently,
randomized phase 2 and phase 3 studies of intravitreal sir-
olimus in non-infectious uveitis are being conducted in
the United States and throughout the world to investigate
the efficacy of sirolimus. Additional QoL analyses of pa-
tients enrolled in these larger randomized control trials
with sirolimus will be very helpful to determine if siroli-
mus is effective in not only controlling the disease but also
beneficial in improving the quality of life of patients suf-
fering from non-infectious uveitis.
Conclusions
Locally delivered sirolimus has demonstrated bioactivity
as an IMT and corticosteroid-sparing agent to treat non-
infectious uveitis. Patients receiving intravitreal injection
of sirolimus showed overall improvement of vision-
related health while those receiving subconjunctival
injections did not. Larger randomized control trials with
sirolimus are indicated to validate these results.
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